Efficacy of hyperthermic isolated limb perfusion for extremity-confined recurrent melanoma

Annals of Surgical Oncology

Volumn 5, Issue 4, 1998, Pages 376-383

  Brobeil, Andrea ^a   Berman, Claudia ^a   Cruse, C Wayne ^a   De Conti, Ronald ^a   Cantor, Alan ^a   Lyman, Gary H ^a   Joseph, Emmanuella ^a   Rapaport, David ^a   Wells, Karen ^a   Reintgen, Douglas S ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Extremity; Hyperthermic isolated limb perfusion; Malignant melanoma; Recurrence; Regional chemotherapy

Indexed keywords

AGED; ARTICLE; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HYPERTHERMIC THERAPY; LIMB PERFUSION; MAJOR CLINICAL STUDY; MALE; MELANOMA; PATIENT SELECTION; PRACTICE GUIDELINE; TREATMENT INDICATION; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; EXTREMITIES; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; MALE; MELANOMA; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PERFUSION; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 17644434927     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02303503     Document Type: Article

References (26)

1. McBride CM, Sugarbaker EV, Hickey RC. Prophylactic isolation-perfusion as the primary therapy for invasive malignant melanoma of the limbs. Ann Surg 1975;182:316.
2. Reinigen DS, Cox C, Slingluff CL, et al. Recurrent malignant melanoma: the identification of prognostic factors to predict survival. Ann Plast Surg 1992;28:45.
3. Balch CM, Soong S-J, Bartolucci AA, et al. Efficacy of an elective lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg 1996;224:255.
4. McClay EF, Mastragelo MJ, Sprandio JD, et al. The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma. Cancer 1989;63:1292.
5. Creech OJ, Krementz ET, Ryan RF, Winblad JN. Chemotherapy of cancer. Regional perfusion using an extracorporeal circuit. Am Surg 1958;148:616.
6. Krementz ET, Ryan RF. Chemotherapy of melanoma of the extremity by perfusion. Fourteen year clinical experience. Ann Surg 1972;175:900.
7. Reinigen DS, Cruse CW, Wells KE, Saba HI, Slingluff CL Jr. Isolated limb perfusion for recurrent melanoma of the extremily. Ann Plast Surg 1992;28:50.
8. Stehlin JS. Hyperthermic perfusion with chemotherapy for cancer of the extremity. Surg Cynecol Obstet 1969;129:305.
9. Olszewski WL, Grzelak I, Ziolkowaska A, Engeset A. Effect of local hyperthermia on lymph immune cells and lymphokines of normal human skin. J Surg Oncol 1989;41:109.
10. Van Ginkel RJ, Hoekstra HJ, Eggermont AMM, et al. Isolated limb perfusion of an irradiated foot with tumor necrosis factor, interferon, and melphalan. Arch Surg 1996;131:672.
11. Edwards MS, Soong SJ, Boddie AN, et al. Isolated limb perfusion for localized melanoma of the extremity. Arch Surg 1990;128:317.
12. Fraker DL, Alexander HR, Andrich M, Rosenburg S. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor and interferon-gamma: Results of a tumor necrosis factur doseescalation study. JCO 1996;14:479.
13. Cohen MH, Ketcham AS, Felix EL, et al. Prognostic factors in patients undergoing lymphadenectomy for malignant melanoma. Ann Surg 1977;186:635.
14. Wong JH, Wanek L, Chang LC, et al. The importance of anatomic site in prognosis with cutaneous melanoma. Arch Surg 1991;126: 486.
15. Karakousis CP, Temple DF, Moore R, Ambrus L. Prognostic parameters in recurrent malignant melanoma. Cancer 1983;52:575.
16. Shaw HM, Beattie CW, McCarrthy WH, Milton GW. Late relapse from cutaneous stage I malignant melanoma. Surg 1985;120:1155.
17. Shaw HM, Balch CM, Soong SJ, Milton GW, McCarthy WH. Prognostic histopathological factors in malignant melanoma. Pathology 1986;17:271.
18. Markowitz JS, Cosini LA, Carey RW, et al. Prognosis after initial recurrence of cutaneous melanoma. Arch Surg 1991;126:703.
19. Klein ES, Den-Ari GY. Isolation perfusion with cisplatin for malignant melanoma of the limbs. Cancer 1987;59:1068.
20. Van der Hoop RG, Vecht CJ, van der Burg ME, et al. Prevention of cisplatin neurotoxicity with an ACTH (4-9) analogue in patients with ovarian cancer. N Engl J Med 1990;322:89.
21. Lienard D, Ewalenko P, Delmotte JJ, et al. High dose recombinant tumor necrosis factor alpha in combination with Interferon gamma and melphalan in isolation perfusion of the limbs for melanomas and sarcomas. JCO 1992;1:5260.
22. Fenn NJ, Horgan K, Johnson RC, Hughes LE, Mansel RE. A randomized controlled trial of prophylactic isolated cytotoxic perfusion for poor-prognosis primary melanoma of the lower limb. Eur J Surg Oncol 1997;23(1):6.
23. Ross M. Results of randomized surgical trials for melanoma. 6th World Congress on Cancers of the Skin. Buenos Aires, Argentina, 1995. Abstract.
24. Klop WMC, Vrouenraets BC, van Geel BN, et al. Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs. J Am Coll Surg 1996;182:467.
25. Gutman M, Abu-Abid S, Inbar M, et al. Intra-arterial chemotherapy with concomitant hemofiltration (chemofiltration) for treatment of loco-regional or pelvic metastases from malignant melanoma. Melanoma Research 1996;6:167.
26. Thompson J. Vascular isolation techniques for regional chemotherapy. Sydney: University of Sydney; 1996. Thesis.